| Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study) | Circulation | 2017 | 182 |
| Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study | Lancet Diabetes and Endocrinology,the | 2017 | 148 |
| Optimizing Cholesterol Treatment in Patients With Muscle Complaints | Journal of the American College of Cardiology | 2017 | 133 |
| Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study | Circulation: Heart Failure | 2017 | 104 |
| Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2 | Journal of Hypertension | 2017 | 97 |
| Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up | Circulation | 2017 | 92 |
| Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs | Journal of Clinical Lipidology | 2017 | 80 |
| Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications | Circulation: Cardiovascular Genetics | 2017 | 75 |
| Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism | Circulation | 2017 | 63 |
| Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia | Journal of Clinical Lipidology | 2017 | 53 |
| The renaissance of lipoprotein(a): Brave new world for preventive cardiology? | Progress in Lipid Research | 2017 | 46 |
| Impact of acute atrial fibrillation termination and prolongation of atrial fibrillation cycle length on the outcome of ablation of persistent atrial fibrillation: A substudy of the STAR AF II trial | Heart Rhythm | 2017 | 31 |
| Knowns and unknowns in the care of pediatric familial hypercholesterolemia | Journal of Lipid Research | 2017 | 29 |
| Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents | Current Opinion in Lipidology | 2017 | 27 |
| Prognostic value of segment involvement score compared to other measures of coronary atherosclerosis by computed tomography: A systematic review and meta-analysis | Journal of Cardiovascular Computed Tomography | 2017 | 26 |
| Novel protein biomarkers associated with coronary artery disease in statin-treated patients with familial hypercholesterolemia | Journal of Clinical Lipidology | 2017 | 18 |
| Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure | Circulation: Cardiovascular Quality and Outcomes | 2017 | 17 |
| World Heart Federation Cholesterol Roadmap | Global Heart | 2017 | 15 |
| Reverse cascade screening for familial hypercholesterolemia in high-risk Chinese families | Clinical Cardiology | 2017 | 13 |
| Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management | Atherosclerosis | 2017 | 3 |
| The value of counting WHO-defined cardiovascular risk factors for death and disability in a national sample of adults with psychosis | Schizophrenia Research | 2017 | 3 |
| Comparison of Safety and Efficacy of Unfractionated Heparin Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention | Heart Lung and Circulation | 2017 | 1 |
| The role of arterial elasticity and cardiovascular peripheral resistance as clinically relevant indices of health status in people with psychosis | Schizophrenia Research | 2017 | 1 |
| Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia | BMJ Open | 2017 | 1 |
| Impact of the Australian gender specific thresholds using the Abbott high sensitivity troponin I assay in clinical care | Pathology | 2017 | 0 |
